We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+15.22%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$349M
AUM Growth
+$70.6M
Cap. Flow
+$59.4M
Cap. Flow %
17.01%
Top 10 Hldgs %
68.99%
Holding
46
New
13
Increased
6
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$22.8M
2
DERM
Dermira, Inc.
DERM
+$22.1M
3
RXDX
Ignyta, Inc.
RXDX
+$19.6M
4
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$18.4M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$14.1M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$23.4M
2
CMRX
Chimerix, Inc.
CMRX
+$6.64M
3
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$6.2M
4
VCEL icon
Vericel Corp
VCEL
+$5.35M
5
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$4.07M

Sector Composition

Rank Sector Weight
1 Healthcare 73.78%
2 Technology 2.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
1
DELISTED
Adamas Pharmaceuticals
ADMS
$31.9M 9.14%
2,109,099
– –
VNDA icon
2
Vanda Pharmaceuticals
VNDA
$307M
$30.3M 8.67%
2,705,758
-25,452
-0.9% -$246K
SGYP
3
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$28.8M 8.26%
7,590,000
+5,415,000
+249% +$18.4M
EXEL icon
4
Exelixis
EXEL
$13.3B
$25M 7.16%
3,200,000
-696,113
-18% -$4.01M
DERM
5
DELISTED
Dermira, Inc.
DERM
$23.4M 6.7%
+800,000
New +$22.1M
BLUE
6
DELISTED
bluebird bio
BLUE
$21.6M 6.2%
38,600
+8,250
+27% +$4.67M
NBIX icon
7
Neurocrine Biosciences
NBIX
$16.8B
$21.4M 6.12%
470,000
+144,700
+44% +$6.66M
EGRX
8
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$21.3M 6.09%
+548,290
New +$22.8M
ZGNX
9
DELISTED
Zogenix, Inc.
ZGNX
$19.6M 5.63%
2,440,959
+355,000
+17% +$3.46M
RXDX
10
DELISTED
Ignyta, Inc.
RXDX
$17.6M 5.03%
3,238,703
+2,951,530
+1,028% +$19.6M
ENTA icon
11
Enanta Pharmaceuticals
ENTA
$366M
$11.9M 3.4%
+538,024
New +$14.1M
SAGE
12
DELISTED
Sage Therapeutics
SAGE
$9.94M 2.85%
+330,000
New +$11M
TTPH
13
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$9.89M 2.83%
114,976
-67,684
-37% -$6.2M
CNXR
14
DELISTED
Connecture, Inc.
CNXR
$9.33M 2.67%
4,127,232
– –
XNCR icon
15
Xencor
XNCR
$1.5B
$8.55M 2.45%
450,000
-78,692
-15% -$1.08M
AUPH icon
16
Aurinia Pharmaceuticals
AUPH
$1.91B
$7.19M 2.06%
2,457,144
– –
ARCT icon
17
Arcturus Therapeutics
ARCT
$164M
$6.35M 1.82%
202,082
-86,513
-30% -$2.73M
RPTP
18
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$5.25M 1.5%
978,350
-367,994
-27% -$1.89M
SRPT icon
19
CALL
Sarepta Therapeutics
SRPT
$1.57B
$4.56M 1.3%
238,900
+88,900
+59% +$1.65M
VIRX
20
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.48M 1.28%
38,924
-362
-0.9% -$40.1K
APYX icon
21
Apyx Medical
APYX
$173M
$4.39M 1.26%
2,680,000
– –
ARDM
22
DELISTED
Aradigm Corp Common Stock
ARDM
$4.38M 1.26%
1,002,962
– –
ITCI
23
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.88M 1.11%
+100,000
New +$3.59M
OCRX
24
DELISTED
Ocera Therapeutics, Inc.
OCRX
$3.73M 1.07%
1,963,777
– –
MCRB icon
25
PUT
Seres Therapeutics
MCRB
$46.8M
$3.49M 1%
+6,000
New +$3.52M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2016 Portfolio in Review

As of Q2 2016, Great Point Partners held 46 positions worth $349M, up 25% from $279M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Great Point Partners deployed $59.4M of net new capital in Q2 2016, opening 13 new positions and adding to 6 existing holdings. Its largest new stake was Eagle Pharmaceuticals, Inc.: 548,290 shares worth $21.3M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 69% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Tetraphase Pharmaceuticals, Inc., an estimated $6.2M trimmed.

  • Great Point Partners's largest Q2 2016 buy was Eagle Pharmaceuticals, Inc.: 548,290 shares worth $21.3M.
  • Great Point Partners added most to Ignyta, Inc. in Q2 2016, an estimated $19.6M increase.
  • Great Point Partners's biggest Q2 2016 reduction was Tetraphase Pharmaceuticals, Inc., cutting an estimated $6.2M.
  • Great Point Partners fully exited Five Prime Therapeutics, Inc. in Q2 2016, selling an estimated $23.4M.
  • Great Point Partners's ten largest holdings make up 69% of its $349M portfolio in Q2 2016.
  • Great Point Partners opened 13 new positions and closed 7 in Q2 2016.
  • Great Point Partners's portfolio value rose 25% quarter-over-quarter to $349M.

Based on Great Point Partners's 13F filing for Q2 2016, filed 15 Aug 2016.